News Releases

Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the NASPGHAN Annual Meeting 2020

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 26, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases today announced that data from the Company’s maralixibat studies will be

Mirum Pharmaceuticals Announces Partnership With EVERSANA to Support Launch and Commercialization of Maralixibat for Alagille Syndrome in the United States

Agreement outlines commercialization and distribution services to support patients diagnosed with Alagille syndrome FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 15, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Oct. 13, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on October 9, 2020 , the

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on September 10, 2020 ,

Mirum Pharmaceuticals to Present at Investor Conferences in September

FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will present at the following virtual

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program

- Maralixibat would be the first treatment available for use in Alagille syndrome, if approved - Completion of the NDA submission expected in the first quarter of 2021 - Expanded Access Program for maralixibat now open FOSTER CITY, Calif. --(BUSINESS WIRE)--Sep.

Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020

Maralixibat demonstrates significant transplant-free survival for patients with progressive familial intrahepatic cholestasis (PFIC2) who achieved serum bile acid (sBA) control in five-year analysis (p=0.0006). sBA responders remain on maralixibat for more than five years with improvements across

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 11, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that the Compensation

Mirum Pharmaceuticals to Present at the Canaccord Genuity 40th Annual Growth Conference

FOSTER CITY, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that Chris Peetz , president and chief executive officer

Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

Rolling NDA submission for maralixibat in Alagille syndrome (ALGS) to be initiated in third quarter 2020; planning for potential launch in second half of 2021. Submission of European marketing authorization application for maralixibat in PFIC2 planned for fourth quarter of 2020.

News Releases

News Releases

Header Menu